Mesa Biotech has been acquired by Thermo Fisher Scientific for four-hundred and fifty million dollars. Under the agreement terms, Thermo Fisher will pay up to an additional one-hundred million dollars upon achieving specific breakthroughs, following the close of the transaction. In addition, the deal, subject to regulatory approval and other customary closing conditions, is scheduled to be completed in the first quarter of 2021.
Executive Vice President and CPO, Thermo Fisher Scientific, Mark Stevenson, stated: "Mesa Biotech's innovative platform will enable us to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19. The addition of Mesa Biotech's easy-to-use, rapid PCR-based test is highly complementary to our existing offering and will further help us meet the continuing demand for COVID-related testing while we work to rapidly scale and develop point-of-care tests for other infectious diseases in the future."
“Mesa Biotech has been acquired by Thermo Fisher Scientific.“
President and CEO, Mesa Biotech, Ingo Chakravarty, stated: "I am extremely proud of the remarkable accomplishments Mesa Biotech has achieved to date and excited about the prospects of becoming a part of Thermo Fisher. Mesa's innovative rapid PCR platform technology, combining PCR accuracy with mobility and test results in thirty minutes, has already played a meaningful role in the collective efforts combating the pandemic. Thermo Fisher's scale, innovation, and global reach will allow us to more significantly amplify the impact our technology will have on human health, during the pandemic and far beyond."